A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Clinical trial NCT07689812 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07689812
Sponsor: Natera, Inc.
Status: NOT_YET_RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Carcinoma)NSCLC Melanoma (Skin Cancer)Melanoma (Skin) Stage IV CRC MSI High Colorectal Cancer DMMR Colorectal Cancer RCC, Renal Cell Cancer RCC Solid Tumors

Start date: 2026-12-01
Primary completion: 2033-12-01
Enrollment: 920

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.